Search results
Results From The WOW.Com Content Network
GVD is a chemotherapy regimen, used for salvage treatment of relapsed or refractory Hodgkin disease, including those patients who relapse after stem cell transplantation. [1]
gemcitabine, cisplatin gemcitabine, dexamethasone, and cisplatin bladder cancer: GDP gemcitabine, dexamethasone, cisplatin: Non-Hodgkin lymphomas and Hodgkin lymphoma: GemOx or GEMOX: gemcitabine, oxaliplatin: Non-Hodgkin lymphomas: GVD: gemcitabine, vinorelbine, pegylated liposomal doxorubicin: Hodgkin lymphoma: GemOx-R or GEMOX-R or R-GemOx ...
Gemcitabine is a synthetic pyrimidine nucleoside prodrug—a nucleoside analog in which the hydrogen atoms on the 2' carbon of deoxycytidine are replaced by fluorine atoms. [ 3 ] [ 24 ] [ 25 ] The synthesis described and pictured below is the original synthesis done in the Eli Lilly Company labs.
Cisplatin is a chemical compound with formula cis-[Pt(NH 3) 2 Cl 2]. It is a coordination complex of platinum that is used as a chemotherapy medication used to treat a number of cancers . [ 3 ] These include testicular cancer , ovarian cancer , cervical cancer , bladder cancer , head and neck cancer , esophageal cancer , lung cancer ...
Cisplatin and derivatives include cisplatin, carboplatin and oxaliplatin. [37] [38] They impair cell function by forming covalent bonds with the amino, carboxyl, sulfhydryl, and phosphate groups in biologically important molecules. [41] Non-classical alkylating agents include procarbazine and hexamethylmelamine. [37] [38]
Accepting the review's recommendations, the government advised that NHS hospitals should phase out the use of the LCP over the next 6–12 months, and that "NHS England should work with clinical commissioning groups (CCGs) to bring about an immediate end to local financial incentives for hospitals to promote a certain type of care for dying ...
Most major toxicities of cisplatin, especially nephrotoxicity, were also reduced in the group of patients treated with lipoplatin and treatment did not require hospitalisation for lipoplatin patients. Median survival times were 10 months for the lipoplatin arm and 8 months for the cisplatin arm, with a ‘’p’’-value of 0.155.
The Patient Advice and Liaison Service (PALS), also known as the Patient Advice and Support Service (PASS) in Scotland, is a National Health Service body created to provide advice and support to NHS patients and their relatives and carers. The scheme was announced in the NHS Plan 2000. Pilot schemes were set up in 2001, with full nationwide ...